Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has maintained a Neutral rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $9 to $8.
November 06, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Pacific Biosciences and lowered the price target from $9 to $8.
The lowering of the price target by Piper Sandler from $9 to $8 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Pacific Biosciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100